Shares of Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) saw unusually-strong trading volume on Tuesday. Approximately 6,444 shares were traded during mid-day trading, an increase of 97% from the average daily volume of 3,275 shares. The stock last traded at $11.69 and had previously closed at $11.68.
Bavarian Nordic Stock Performance
The firm has a market cap of $2.81 billion, a price-to-earnings ratio of 21.45 and a beta of 1.33. The business has a 50 day simple moving average of $11.49 and a 200-day simple moving average of $10.22.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported $0.28 earnings per share (EPS) for the quarter. Bavarian Nordic had a return on equity of 11.97% and a net margin of 24.36%. The business had revenue of $277.86 million during the quarter.
Bavarian Nordic Company Profile
Bavarian Nordic is a Danish biotechnology company that develops, manufactures and markets vaccines for infectious diseases and cancer immunotherapy. Founded in 1994, the company is based in Denmark and serves markets in Europe, North America and other regions. Its best-known vaccine is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, for protection against smallpox and mpox. Bavarian Nordic also offers vaccines for diseases including rabies, tick-borne encephalitis, typhoid fever and cholera.
Featured Articles
- Five stocks we like better than Bavarian Nordic
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
